Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
Brenner B, Geva R, Rothney M, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Gluzman A, Purim O, Shacham-Shmueli E, Shulman K, Mishaeli M, Man S, Soussan-Gutman L, Tezcan H, Chao C, Shani A, Liebermann N. Brenner B, et al. Among authors: mishaeli m. Value Health. 2016 Jan;19(1):82-7. doi: 10.1016/j.jval.2015.08.013. Epub 2015 Oct 30. Value Health. 2016. PMID: 26797240 Free article.
Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I, Goshen-Lago T, Sternschuss M, Morgenstern S, Geva R, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Shulman K, Mishaeli M, Man S, Liebermann N, Soussan-Gutman L, Brenner B. Ben-Aharon I, et al. Among authors: mishaeli m. Oncologist. 2019 Aug;24(8):e696-e701. doi: 10.1634/theoncologist.2018-0351. Epub 2019 Feb 12. Oncologist. 2019. PMID: 30755502 Free PMC article.
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Roisman LC, Bar J; Israel Lung Cancer Group. Dudnik E, et al. Among authors: mishaeli m. J Thorac Oncol. 2018 Aug;13(8):1128-1137. doi: 10.1016/j.jtho.2018.04.024. Epub 2018 Apr 30. J Thorac Oncol. 2018. PMID: 29723688 Free article.
A comparison of two dose regimens in pancreatic cancer.
Figer A, Sadikov E, Mishaeli M, Koren R, Gal R, Levin I, Klein B. Figer A, et al. Among authors: mishaeli m. J Chemother. 2000 Oct;12(5):442-5. doi: 10.1179/joc.2000.12.5.442. J Chemother. 2000. PMID: 11128566 Clinical Trial.
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M; Israel Lung Cancer Group. Dudnik E, et al. Among authors: mishaeli m. Clin Lung Cancer. 2019 Jul;20(4):278-286.e1. doi: 10.1016/j.cllc.2019.03.007. Epub 2019 Apr 5. Clin Lung Cancer. 2019. PMID: 31060855
Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A, Peled N, Maimon Rabinovich N, Mishaeli M, Shochat T, Zer A, Rotem O, Allen AM, Bar J, Dudnik E; On behalf of the Israel Lung Cancer Group. Bedas A, et al. Among authors: mishaeli m. Oncol Res Treat. 2019;42(5):275-282. doi: 10.1159/000499086. Epub 2019 Apr 5. Oncol Res Treat. 2019. PMID: 30955009
24 results